Short stature in Noonan syndrome: response to growth hormone therapy

J M W Kirk, P R Betts, G E Butler, M D C Donaldson, D B Dunger, D I Johnston, C J H Kelnar, D A Price, P Wilton, the UK KIGS Executive Group on behalf of the participating centres

Abstract

Background—Growth hormone (GH) has been used to promote growth in both the short and long term in a number of dysmorphic syndromes, including Turner syndrome. As this condition shares many clinical features with Noonan syndrome, it would seem logical to treat the latter group with GH.

Aims—To assess the short and long term response to GH therapy in patients with Noonan syndrome.

Methods—Analysis of patients with Noonan syndrome in the Pharmacia & Upjohn International Growth Study (this post-marketing database contains data on the majority of patients currently treated with GH in the UK). A questionnaire was also sent to participating clinicians.

Results—Data on 66 patients (54 males) were available for study. At the start of GH therapy children were short, compared with both normal and Noonan children. During the first year of GH therapy height velocity increased from a mean of 4.9 to 7.2 cm per year. For patients treated long term with GH, mean height SDS increased from −2.9 pretreatment to −2.6 after one year and −2.3 after five years. Of the 10 patients at near final height, only one had a height above the 3rd centile for normal adults and above the mean for untreated Noonan patients. The mean increment in final height was 3.1 cm (range −1.1 to 6.5 cm).

Conclusions—GH therapy in patients with Noonan syndrome will improve height velocity in the short term. Longer-term therapy results in a waning of effect; initial indications are that final height is not improved substantially in most patients.

Keywords: Noonan syndrome; short stature; growth hormone

Noonan syndrome, a constellation of dysmorphic features initially described in 1963, occurs with a prevalence of approximately 1 in 1000. Dominant inheritance with incomplete penetrance is often found in affected families, and the gene for Noonan syndrome has now been mapped to chromosome 12p. At present, the diagnosis is a clinical one and a number of scoring systems exist. Short stature is common, with 83% of affected children in one series having a height below the 3rd centile.

Another study of 144 patients showed that birth weight is usually normal, with poor prepubertal growth and delayed puberty. Final height is often compromised, with mean adult height for males 162.5 cm, and for females 152.7 cm.

The cause of the short stature in Noonan syndrome is unclear. Although insulin like growth factor 1 (IGF-1) concentrations are reported as low or low normal, formal anterior pituitary function testing is usually normal, as is spontaneous growth hormone secretion. Other endocrine abnormalities described include hypogonadism and autoimmune thyroiditis.

Noonan syndrome shares many phenotypic features with Turner syndrome; it was previously referred to as “male Turner’s”, although males and females are affected with an equal sex incidence. Because of the clinical similarities between Noonan and Turner syndrome, and because growth hormone can improve short term growth and final height in patients with Turner syndrome, it would appear logical to treat patients with Noonan syndrome.

This report analyses those patients with Noonan syndrome from the UK who have been treated with growth hormone and whose growth data have been analysed in the Pharmacia & Upjohn International Growth Study (KIGS). This is an international post-marketing surveillance database of children with various growth disorders treated with growth hormone (GH). The database was established in 1987, and now includes data on over 30 000 patients in 43 countries. Within the UK, data on 4400 patients (2350 ongoing) from 40 centres are now loaded onto the database, and represent over two thirds of the total UK paediatric population currently treated with GH.

Patients and methods

All patients with a clinical diagnosis of Noonan syndrome (Code 3.3.2) on the UK KIGS database were included. In addition to the biochemical and auxological data on the database, all Noonan patients have a further disease specific sheet which provides further clinical details. We also requested further data by questionnaire from clinicians as to whether the patient had received oxandrolone, testosterone, or oestrosten in addition to GH; how often echocardiography had been performed during GH therapy; and if applicable, the reasons for stopping GH and the outcome thereafter.

Reference data were drawn from the standards of Tanner and Whitehouse for normal children, and Ranke and colleagues for...
Noonan children. Bone ages were calculated using the method of Tanner and colleagues. The results are shown as mean (SD) where appropriate. Statistical analysis was by SAS, version 6.12/AIX.

Results

A total of 66 patients with Noonan syndrome (54 males, 82%) have been included. Subjective overall assessment of the features of Noonan syndrome by the referring clinician was minor in 22%, moderate in 65%, and severe in 13%. Seventy eight per cent of patients had a cardiac malformation, and 48% had had corrective cardiac surgery. Of the males, 67% gave a history of cryptorchidism. Twenty five per cent had a family history of Noonan syndrome.

Pretreatment Data

Table 1 and fig 1 show pretreatment and first year therapy data. As there was no significant difference between the two sexes, data were pooled. Information on birth weight was available in 53 children; mean birth weight standard deviation score (BwSDS) was −0.5 for all patients. Fifty five patients had anterior pituitary function assessed, with a mean (SD) GH peak of 16.8 (10.2) ng/ml (normal >10).

At commencement of GH, children were short compared to both the normal and Noonan population (mean (SD) height SDS: −2.9 (0.7) and −1.2 (0.8) respectively). At start of therapy, mean (SD) age was 10.2 (3.3) years, and bone age (only available in 27 children) was delayed by a mean of 2.7 "years". Seven were already in established puberty. Six patients were additionally receiving thyroxine.

First Year of GH Therapy

The mean (SD) dose of GH was 0.79 (0.24) U/kg/week, with the majority of patients receiving seven injections per week. During the first year of GH therapy, height velocity (n = 35) increased from a pretreatment mean (SD) of 4.8 (1.1) to 7.2 (1.7) cm/y (p < 0.05; fig 1). When expressed as height velocity SDS scores, the mean (SD) rose from −0.9 (1.8) to 1.9 (2.5) (p < 0.05). During the same period the mean height SDS rose by 0.3 and 0.4 for normal and Noonan populations respectively (both p < 0.05). Bone age increased by a mean (SD) of 1.0 (0.7) "years" during the year of therapy.

Long Term Therapy

Patients have continued on GH therapy for up to six years (fig 2), although the numbers have steadily declined to only 13 patients treated at the end of this period. Height SDS increased from a mean (SD) of −2.9 (0.7) at the start of GH therapy to −2.6 (0.8) after one year of therapy, and −2.3 (0.7) (n = 13) after six years. When plotted using Noonan data the mean (SD) height SDS increased from −1.1 (0.8) to −0.7 (0.9) after one year of GH therapy to −0.3 (0.9) after six years. Although the increase between height SDS for both normal and Noonan data was significantly greater after three years of GH therapy compared to one, the sixth year data was not. The dose of GH fell progressively to a mean of 0.63 U/kg/week after six years, although the number of injections remained at seven per week in the majority of patients throughout the course of treatment. Eleven patients have received additional therapy with either oxandrolone, testosterone, or oestrogen.

Reasons for stopping GH included cardiac decompensation (n = 1) and worsening of kyphoscoliosis (n = 1); one patient had their GH stopped for a month when they developed headache and vomiting (but no papilloedema). Other reasons were poor growth (n = 6), non-compliance (n = 4), and the patient’s decision to stop therapy (n = 3). Echocardiograms were performed yearly in 40%, and two yearly in 20%; in 14% of patients, none were performed while on therapy.

Final Height

Data are available on 10 patients with Noonan syndrome treated to near final height (defined as >15 years in girls and >17 years in boys, and with a height velocity <2.5 cm/y; table 2). Mean final height was 147.2 cm (range 142.9–151.4) in girls and 159.9 cm (range 155.6–
phenomenon has also been noted in other patients on the KIGS international database, and presumably reflects the selection criteria used in these patients.

The patients in this study were growing slowly pretreatment, and had a significant increase in height velocity during the first year of GH therapy. After three years of continuous treatment there was no further increase in height SDS, either compared with normal or Noonan children. This is despite the fact that those children who were growing poorly were either stopped or made the decision themselves to stop GH therapy. In addition, final height data in these patients was relatively disappointing, with a mean increase in final height of only 3.1 cm, and only the minority having an increase of >5 cm. Although there may be some underestimation of final height (as a number of patients were still growing at the end of the study), it is unlikely that this difference would be substantial as the mean height velocity was only 0.8 cm/y in this group. In addition, although three patients did have final heights within their genetically predicted range (target height ±10 cm), even this may be unhelpful as a number had parents affected with Noonan syndrome (as would be expected from an autosomally dominant inherited disorder).

Untreated Noonan patients continue to grow into their late teens (a mean of 2.0 cm for girls, and 8.6 cm for boys from the age of 17 years); assessment of changes in height SDS for chronological age using Noonan standards in patients treated with GH are therefore likely to overestimate height gains. As not all patients had pretreatment bone ages performed, and as extrapolation of the pretreatment height centile to adult height on disease specific charts has been found to be superior to both Tanner–Whitehouse and Bayley–Pinneau methods of height prediction in Turner syndrome, we have chosen the former method to predict untreated final height.

The growth response of patients with Noonan syndrome to GH has previously been assessed in a number of studies. Cotterill and colleagues showed a significant increase in height velocity of more than 2 cm/y in 24/30 patients over one year. Both Tanaka and De Schepper and colleagues noted that the
Short stature in Noonan syndrome

Responses to GH in patients with Noonan syndrome were similar to those with Turner syndrome. In the International KIGS study, which looked at 55 patients, a lower dose of GH was used (median 0.61 U/kg/week) and produced an increase in height velocity from a median of 4.3 cm/y pretreatment to 7.0 cm/y after one year. Height SDS showed a median increase of 0.5 for normal and 0.2 for Noonan standards during the first year of therapy, but with a subsequent waning of effect over the subsequent years, with only small numbers of patients treated (n = 11).

Information on long term therapy is often limited to small numbers of patients in other studies. The National Cooperative Growth Study evaluated the response to GH in 150 patients with Noonan syndrome. These children were significantly shorter than those with idiopathic GH deficiency (IGHD) and Turner syndrome, with growth rates for years 1, 2, 3, and 4 intermediate for that between IGHD and Turner syndrome. There was a significant improvement in height SD scores in those 42 children who were monitored for at least four years of GH therapy. Three out of six boys who achieved adult height exceeded pretreatment predicted heights. In the International KIGS study containing 143 patients, there was an increase in height SDS (Noonan standards) of 0.5 SDS for boys and 1.1 SDS for girls after three years of GH therapy. A subgroup treated with GH showed a mean increase in height SDS of 1.5 for Tanner and 2.4 for Noonan standards. In another study, final height in patients treated (n = 11).

We would like to acknowledge the assistance of all contributing centres to the KIGS database, which is sponsored by Pharmacia & Upjohn.